Twitxy Saved

Natalie Vokes

@NIVokes

Asst professor @MDAndersonNews. Lung cancer and clinical computational oncology. Tweets are my own.
Houston, TX Joined March 2013
338 Following 710 Followers 151 Posts

Latest posts 5

Natalie Vokes @NIVokes
Looking forward to participating in this unique virtual congress covering the present and future of lung cancer management. Registration and event details here: oncodaily.com/lungo-2026-vir…!
oncodaily.com LungÕ 2026 – Virtual Global Congress on Lung Oncology - Oncology News, Insights, Stories by... LungÕ 2026 – Virtual Global Congress on Lung Oncology is an international virtual medical congress dedicated to lung oncology, focusing on early detection,
OncoDaily Verified account @oncodaily Oct 23
Meet our LungÕ 2026 speaker: Natalie Vokes!

We’re delighted to welcome Dr. Natalie Vokes, Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States, to LungÕ 2026 – Virtual Global Congress on Lung Oncology.

Join us for a global exchange of ideas on advancing lung cancer care.

📅 November 5, 2026

🌐 Virtual congress

@NIVokes

👉 Register here:

oncodaily.com/lungo-2026-vir…
View quoted post on X
Natalie Vokes @NIVokes
Delighted to share this multi-institutional collaboration dissecting outcomes in sarcomatoid lung cancer, a rare and hard to treat subtype. While chemotherapy may have limited efficacy, we found that many of these tumors are PDL1 high and responsive to immunotherapy.
JTO & JTO CRR Verified account @JTOonline Dec 20, 2025
Outcomes to ICIs and genomic features in PSC remain underexplored compared with other NSCLC subtypes. Hong et al. present the findings from their multicenter retrospective study on clinicogenomic features and #immunotherapy associations in PSC. bit.ly/3MDgrTX @NIvokes
View quoted post on X
Natalie Vokes @NIVokes
Great to see so much data coming out in this space, with many clinical trials now available or coming for patients with MTAP deletions including at @MDAndersonNews and other centers
Benjamin Besse @BenjaminBesseMD Sep 9, 2025
Be ready to screen MTAP loss in all pts with advanced NSCLC, regardless of driver.
@mihaela_aldea shows incidence, highest in ALK/RET/EGFR/ROS1.
AMG193 paved the way at #ESMO24.
BMS-986504 confirms druggability: 29% ORR + many durable SD (slide @CharuAggarwalMD). #WCLC25
View quoted post on X
Natalie Vokes @NIVokes
Thanks to @TargetedOnc for the invitation, had a great time reviewing this data! More nuanced clinical decisions to be made with our patients as our options for front-line EGFR have increased
During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, (@NIVokes) discussed trials of targeted agents for EGFR+ lung cancer. #lcsm | @MDAndersonNews

hubs.li/Q03cjhfK0
View quoted post on X